Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Advertisement

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 30.09.20 in Vol 1, No 1 (2020): Jan-Dec

This paper is in the following e-collection/theme issue:

    Peer-Review Report

    Authors’ Response to Peer Reviews of “No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19”

    1Medinsight Research Institute, Rehovot, Israel

    2Program in Impactful Giving, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

    Corresponding Author:

    Moshe Rogosnitzky

    Medinsight Research Institute

    Pekeris 4

    Weizmann Science Park

    Rehovot, 7670204

    Israel

    Phone: 972 522945520

    Email: moshe@medinsight.org



    Author response to peer reviews for “No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.”


    Response to Round 1 Reviews

    Response to Reviewers

    The authors of the manuscript are grateful to the editor and reviewers for their invaluable input and feedback. We have taken the necessary steps to address the comments given and will be providing a summary of the changes made to the manuscript here. We also ensured that we revised the manuscript in line with common formatting/editorial guidelines as listed in JMIRx’s “Instructions for Authors” guide.

    Reviewer E

    The paper is a narrative review that consolidates the extensive evidence in the literature supporting the potential efficacy of six generic drugs (as discussed in the manuscript) in the management of COVID-19 patients. As such, it does not align with the “Introduction, Methods, Results, and Discussion-IMRD” structure that will be expected from an original article. Also, the current structure of the manuscript is in line with similar narrative reviews already published on JMIRx.

    Reviewer F
    Overall

    All nonstandard abbreviations have been removed from the manuscript and use of abbreviations reduced significantly. Also, the authors have ensured that each abbreviation used is well defined at the point of first use.

    We have included new papers (clinical trials) that have been generated since the manuscript was first submitted, as recommended.

    Abstract

    We have included the drug class for each drug and summarized the pathophysiological mechanism through which the drugs may help improve treatment outcomes in patients with COVID-19.

    Background

    Similar to the changes made to the abstract, we also explicitly mentioned the class to which each of the six drugs belongs as well as a summary of their underlying pathophysiological mechanism.

    Pathophysiology of COVID-19 section

    We have stated explicitly that the percentages reported are from hospitalized patients rather than individuals in the community.

    We have also included relevant references in the table and changed the orientation of the table, as recommended.

    As suggested, we have listed the major plasma inflammatory biomarkers that are abnormal in COVID-19, and these are the same as listed in Table 1.

    Potential Therapies Within the Current Pharmacopeia section

    We have restructured the sentence starting with “All three drugs...” to improve clarity and comprehension.

    With respect to Table 2, we have added references from which the data presented for each drug have been sourced.

    Dipyridamole section

    We added a reference for the sentence starting with “Within the 200-400 mg....”

    We have restructured the sentence starting with “Examples include...,” first to improve the overall clarity of the sentence, and second to provide an explanation for “widening the therapeutic window of glucocorticoid activity.”

    Sildenafil section

    We have included trial numbers/identifiers in Table 2 for relevant ongoing clinical trials relating to sildenafil.

    Conclusions

    We modified the sentence beginning with “The efforts we make now to facilitate...” to improve its overall clarity.

    Other minor comments

    We made the headings for Sildenafil and Fenofibrate / Bezafibrate bold for consistency with other similar headings.

    The “V” in SARS-CoV-2 has been capitalized in all cases.

    All page numbers are now sequential.

    Edited by G Eysenbach; This is a non–peer-reviewed article. submitted 21.09.20; accepted 22.09.20; published 30.09.20

    ©Moshe Rogosnitzky, Esther Berkowitz, Alejandro R Jadad. Originally published in JMIRx Med (https://med.jmirx.org), 30.09.2020.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.